Iovance Biotherapeutics announced it has completed its rolling Biologics License Application submission to the U.S. Food and Drug Administration for lifileucel. Lifileucel is a tumor infiltrating lymphocyte therapy intended as a treatment for patients with advanced melanoma who progressed on or after prior anti-PD-1/L1 therapy and targeted therapy, where applicable. There are no FDA approved therapies in this treatment setting. Frederick Vogt, Ph.D., J.D., Interim President and Chief Executive Officer of Iovance, stated, "Completing our BLA submission for lifileucel is a critical step forward in our journey to deliver the first individualized, one-time cell therapy for a solid tumor. I would like to acknowledge the patients and physicians who participated in the C-144-01 clinical trial and the FDA review team for their commitment and support, as well as our internal team for their tremendous effort in completing the first BLA submission for Iovance. Our preparations for commercialization remain on track to support a launch later this year. We look forward to continued collaboration with the FDA as they review this new class of treatment for advanced melanoma patients with limited options."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on IOVA:
- Iovance Biotherapeutics Completes Biologics License Application (BLA) Submission for Lifileucel in Advanced Melanoma
- Iovance says it does not hold deposits, securities at Silicon Valley Bank
- Iovance Biotherapeutics to Present at Upcoming Conferences
- Iovance Biotherapeutics price target lowered to $15 from $25 at Oppenheimer
- Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates